The impact of combining interventions with various annual antiviral treatment rates and increases in harm reduction coverage to achieve fixed targets in the reduction of CHC prevalence (4a) or HCV incidence (4b) among PWID by 2030 (50%, 75% or 85% reduction by 2030 compared to 2016). The bars correspond to scenarios of harm reduction coverage at 44%, 60% and 70% of PWID.
a. Chronic HCV Prevalence among PWID
b. New infections among PWID